Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Asthma

Treatments: Drug: Fluticasone propionate/salmeterol combination; Drug: Inhaled corticosteroids

Study type: Observational

Funder types: Industry

Identifiers

NCT01332344

112604

Details and patient eligibility

About

The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg ("FSC 100/50") or inhaled corticosteriods in typical clinical practice using a retrospective observational cohort study design of large managed care database.

Enrollment: 5,180 patients

Sex: All

Ages: 12 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with asthma as determined by ICD-9 codes and asthma drug use
• at least 12 years of age
• treated with inhaled corticosteroids

Exclusion criteria

• Subjects with COPD or treatment for COPD

Trial design

5,180 participants in 1 patient group

Asthma patients treated with inhaled corticosteroids

Description:

Asthma subjects newly prescribed inhaled corticosteriods

Treatment:

Drug: Inhaled corticosteroids

Drug: Fluticasone propionate/salmeterol combination